Lista de obras -

"Active" cancer immunotherapy by anti-Met antibody gene transfer

artículo científico publicado en 2008

A functional domain in the heavy chain of scatter factor/hepatocyte growth factor binds the c-Met receptor and induces cell dissociation but not mitogenesis ⬇️

artículo científico publicado el 1 de diciembre de 1992

Anti-Differentiation Effect of Oncogenic Met Receptor in Terminally-Differentiated Myotubes

artículo científico publicado en 2015

CD44v6 as innovative sarcoma target for CAR-redirected CIK cells.

artículo científico publicado en 2018

CSPG4-specific CAR.CIK lymphocytes as a novel therapy for the treatment of multiple soft tissue sarcoma histotypes

artículo científico publicado en 2020

Cardiac concentric hypertrophy promoted by activated Met receptor is mitigated in vivo by inhibition of Erk1,2 signalling with Pimasertib.

artículo científico publicado en 2016

Dual Constant Domain-Fab: A novel strategy to improve half-life and potency of a Met therapeutic antibody.

artículo científico publicado en 2016

Identification of Myocardial and Vascular Precursor Cells in Human and Mouse Epicardium

artículo científico publicado en 2007

Inhibition of ligand-independent constitutive activation of the Met oncogenic receptor by the engineered chemically-modified antibody DN30.

artículo científico publicado en 2015

MET overexpression turns human primary osteoblasts into osteosarcomas.

artículo científico publicado en 2006

MET/HGF Co-Targeting in Pancreatic Cancer: A Tool to Provide Insight into the Tumor/Stroma Crosstalk

artículo científico publicado en 2018

MTI-101 (cyclized HYD1) binds a CD44 containing complex and induces necrotic cell death in multiple myeloma

artículo científico publicado en 2013

Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours

scientific article published on 06 February 2019

Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibody

artículo científico publicado en 2010

Quiescent neuronal progenitors are activated in the juvenile guinea pig lateral striatum and give rise to transient neurons

artículo científico publicado en 2014

Rebound Effects Caused by Withdrawal of MET Kinase Inhibitor Are Quenched by a MET Therapeutic Antibody

artículo científico publicado en 2016

T cell receptor (TCR) gene transfer with lentiviral vectors allows efficient redirection of tumor specificity in naive and memory T cells without prior stimulation of endogenous TCR.

artículo científico publicado en 2009

Targeted therapy by gene transfer of a monovalent antibody fragment against the Met oncogenic receptor.

artículo científico publicado en 2013

Targeting the MET oncogene by concomitant inhibition of receptor and ligand via an antibody-"decoy" strategy

artículo científico publicado en 2018

Targeting the oncogenic Met receptor by antibodies and gene therapy

artículo científico

The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation

artículo científico publicado en 2009

The tyrosine kinase encoded by the MET proto-oncogene is activated by autophosphorylation

artículo científico publicado en 1991

Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET.

artículo científico publicado en 2013

Lista de obras de

"Active" cancer immunotherapy by anti-Met antibody gene transfer

A functional domain in the heavy chain of scatter factor/hepatocyte growth factor binds the c-Met receptor and induces cell dissociation but not mitogenesis ⬇️

Anti-Differentiation Effect of Oncogenic Met Receptor in Terminally-Differentiated Myotubes

CD44v6 as innovative sarcoma target for CAR-redirected CIK cells.

CSPG4-specific CAR.CIK lymphocytes as a novel therapy for the treatment of multiple soft tissue sarcoma histotypes

Cardiac concentric hypertrophy promoted by activated Met receptor is mitigated in vivo by inhibition of Erk1,2 signalling with Pimasertib.

Dual Constant Domain-Fab: A novel strategy to improve half-life and potency of a Met therapeutic antibody.

Identification of Myocardial and Vascular Precursor Cells in Human and Mouse Epicardium

Inhibition of ligand-independent constitutive activation of the Met oncogenic receptor by the engineered chemically-modified antibody DN30.

MET overexpression turns human primary osteoblasts into osteosarcomas.

MET/HGF Co-Targeting in Pancreatic Cancer: A Tool to Provide Insight into the Tumor/Stroma Crosstalk

MTI-101 (cyclized HYD1) binds a CD44 containing complex and induces necrotic cell death in multiple myeloma

Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours

Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibody

Quiescent neuronal progenitors are activated in the juvenile guinea pig lateral striatum and give rise to transient neurons

Rebound Effects Caused by Withdrawal of MET Kinase Inhibitor Are Quenched by a MET Therapeutic Antibody

T cell receptor (TCR) gene transfer with lentiviral vectors allows efficient redirection of tumor specificity in naive and memory T cells without prior stimulation of endogenous TCR.

Targeted therapy by gene transfer of a monovalent antibody fragment against the Met oncogenic receptor.

Targeting the MET oncogene by concomitant inhibition of receptor and ligand via an antibody-"decoy" strategy

Targeting the oncogenic Met receptor by antibodies and gene therapy

The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation

The tyrosine kinase encoded by the MET proto-oncogene is activated by autophosphorylation

Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET.